ES2714999T3 - Terapia de combinación que usa inmunoglobulina e inhibidor de C1 - Google Patents

Terapia de combinación que usa inmunoglobulina e inhibidor de C1 Download PDF

Info

Publication number
ES2714999T3
ES2714999T3 ES12761739T ES12761739T ES2714999T3 ES 2714999 T3 ES2714999 T3 ES 2714999T3 ES 12761739 T ES12761739 T ES 12761739T ES 12761739 T ES12761739 T ES 12761739T ES 2714999 T3 ES2714999 T3 ES 2714999T3
Authority
ES
Spain
Prior art keywords
inh
ivig
administered
immunoglobulin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12761739T
Other languages
English (en)
Spanish (es)
Inventor
Milan Basta
Xinzhi Chen
Mark Mattson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Original Assignee
CSL Behring GmbH Deutschland
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland, US Department of Health and Human Services filed Critical CSL Behring GmbH Deutschland
Application granted granted Critical
Publication of ES2714999T3 publication Critical patent/ES2714999T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES12761739T 2011-09-24 2012-09-21 Terapia de combinación que usa inmunoglobulina e inhibidor de C1 Active ES2714999T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538832P 2011-09-24 2011-09-24
PCT/EP2012/068643 WO2013041677A1 (en) 2011-09-24 2012-09-21 Combination therapy using immunoglobulin and c1-inhibitor

Publications (1)

Publication Number Publication Date
ES2714999T3 true ES2714999T3 (es) 2019-05-31

Family

ID=46881067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12761739T Active ES2714999T3 (es) 2011-09-24 2012-09-21 Terapia de combinación que usa inmunoglobulina e inhibidor de C1

Country Status (9)

Country Link
US (1) US10471142B2 (https=)
EP (1) EP2758076B1 (https=)
JP (1) JP6190368B2 (https=)
KR (1) KR101956585B1 (https=)
CN (1) CN104010656B (https=)
AU (1) AU2012311483B2 (https=)
DK (1) DK2758076T3 (https=)
ES (1) ES2714999T3 (https=)
WO (1) WO2013041677A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9352016B2 (en) 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
ES2609070T3 (es) * 2013-02-28 2017-04-18 Csl Behring Gmbh Agente terapéutico para el embolismo de líquido amniótico
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
EP4162947A1 (en) * 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
US20180036394A1 (en) * 2015-02-20 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
WO2022251654A1 (en) * 2021-05-28 2022-12-01 West Virginia University Board of Governors on behalf of West Virginia University Mitoneet ligands for use in protection from tissue ischemic reperfusion injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2009158A (en) * 1934-08-01 1935-07-23 Ophthalmological Foundation In Ophthalmic ergograph
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
US20100143325A1 (en) * 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法

Also Published As

Publication number Publication date
KR20140075753A (ko) 2014-06-19
CN104010656B (zh) 2016-02-24
HK1200334A1 (en) 2015-08-07
CA2848510A1 (en) 2013-03-28
US20140234293A1 (en) 2014-08-21
EP2758076B1 (en) 2018-12-12
AU2012311483B2 (en) 2016-03-10
KR101956585B1 (ko) 2019-03-11
JP2014526541A (ja) 2014-10-06
US10471142B2 (en) 2019-11-12
WO2013041677A1 (en) 2013-03-28
EP2758076A1 (en) 2014-07-30
JP6190368B2 (ja) 2017-08-30
DK2758076T3 (en) 2019-04-01
CN104010656A (zh) 2014-08-27
AU2012311483A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
ES2714999T3 (es) Terapia de combinación que usa inmunoglobulina e inhibidor de C1
ES2407429T3 (es) Vacuna terapéurica
ES2245028T3 (es) Uso de lactoferrina en el tratamiento de trastornos inducidos por alergenos.
AU2005211890B2 (en) Highly concentrated liquid formulations of anti-EGFR antibodies
US20190062428A1 (en) Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
ES2587863T3 (es) Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central
US20160060324A1 (en) Methods and Compositions for Treating Bleeding Disorders
ES2965454T3 (es) Protocolo mejorado para el tratamiento de la nefritis lúpica
Yue et al. Anti-osteosarcoma effect of antiserum against cross antigen TPD52 between osteosarcoma and Trichinella spiralis
MXPA04007311A (es) Tratamiento de ms con suero de cabra.
JP2009545624A (ja) 自己免疫またはアレルギー疾患の治療における線形動物由来のシスタチン
JP7246094B2 (ja) 活性調節剤
JP7351835B2 (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
JP2010535199A (ja) コハク酸を含む鼻腔内医薬品組成物
CA2848510C (en) Combination therapy using immunoglobulin and c1-inhibitor
ES2651537T3 (es) Tratamiento y prevención de la enfermedad de Alzheimer (AD)
HK1200334B (en) Combination therapy using immunoglobulin and c1-inhibitor
CN110882240B (zh) 作为急性缺血性中风的治疗剂的多酚衍生物化合物6-cepn
EP3493832A1 (en) Pharmaceutical formulations of c1 esterase inhibitor
CN101410138A (zh) 作为药用产品的对切昆贡亚热特异的免疫球蛋白的浓缩物
RU2473364C2 (ru) Способ лечения клещевого энцефалита
Somaratne et al. A child with acquired haemophilia
Feng et al. Melatonin and calpeptin synergistically protect against post-reperfusion injury in a rat middle cerebral artery occlusion stroke model
Imhof et al. Miscellaneous antibacterial
JP6488376B2 (ja) 免疫原性を低減するかまたは予防するためのヒト化コブラ毒因子を含む医薬組成物、薬剤および組み合わせ医薬